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ترابط الربوتني الدهين )أ( ومقياس SYNTAX مع 
شدة تصلب الشريان التاجي يف مشال اهلند
فوزية اأ�صفق، بي كي غويل، ناجراجا مورثي، ري�صي �صيثي، حممد اإدري�ض خان، حممد ظفر اإدري�ض
امللخ�ض: الهدف: هدف هذه الدرا�صة املقطعية درا�صة الرتابط بني م�صتويات الربوتني الدهني )اأ( كموؤ�رص لت�صلب ال�رصايني وعالقتها ب�صدة 
360 مري�صا على التوايل يف معهد �صاجناي غاندي للدرا�صات العليا مبعهد العلوم الطبية  ت�صلب ال�رصيان التاجي، الطريقة: مت ت�صجيل 
وم�صت�صفى جامعة امللك جورج الطبية، لكناو، �صمال الهند، من الذين كانوا يعانون من اآالم يف ال�صدر واأعرا�ض ت�صلب ال�رصيان التاجي 
وبنف�ض الوقت كانوا يتناولون عالج تخفي�ض دهون، بني يونيو 2009 واأكتوبر 2011. مت �صحب الدم �صباحا قبل الفطور قبل ت�صوير 
ال�رصيان التاجي لقيا�ض م�صتويات الدهون والربوتني الدهني )اأ(. مت ح�صاب التاآزر بني التدخل التاجي عن طريق اجللد بتاك�صو�ض ومقيا�ض 
جراحة القلب )SYNTAX( وفقا لنتائج ت�صوير ال�رصيان التاجي. مت تق�صيم املر�صى اإىل 3 جمموعات بناء على �صدة اإ�صابة ال�رصيان 
270 مري�صا، وكانت م�صتويات  اإ�صابة ال�رصيان التاجي يف  التاجي ومقيا�ض )SYNTAX(. النتائج: ك�صف ت�صوير االأوعية الدموية 
الربوتني الدهني )اأ( اأعلى عند امل�صابني مبر�ض ال�رصيان التاجي مقارنة بغريهم )48.73 ± 23.85 ملجم / دل مقابل 18.95 11.15 
بامل�صابني  مقارنة  واحد  �رصيان  بت�صّيق  امل�صابني  عند  اأقل  )اأ(  الدهني  الربوتني  م�صتويات  كانت  كما   P >0.0001 دل   / ملجم   ±
اأو ثالثة )39.28 ± 18.41 ملجم / دل مقابل 58،01 22.98 ± ملجم / دل، و69.22 24.13 ± ملجم / دل  بت�صّيق �رصيانني 
 )SYNTAX( كانت م�صتويات الربوتني الدهني )اأ( اأعلى بكثري عند امل�صابني مبر�ض ال�رصيان التاجي ال�صديد مع نقاط .)]P>0.05[
 SYNTAX( )r = 0.70,( اأكرث من 30 )88.16 ± 24.35 ملجم/ دل(. ارتبطت م�صتويات الربوتني الدهني )اأ( ب�صكل كبري مع موؤ�رص
P>0.0001(. اخلال�صة: ثبت يف هذه الدرا�صة الرتابط االإيجابي بني م�صتويات الربوتني الدهني )اأ( وموؤ�رص )SYNTAX( يف االأوعية 
تخفي�ض  التاجية.  القلب  الأمرا�ض  م�صتقل  م�صبب   اختطار  عامل  املرتفع  )اأ(  الدهني  الربوتني  م�صتوى  كان  ذلك،  على  امل�صابة. وعالوة 
م�صتويات  الربوتني الدهني )اأ( �صوف تقلل االإ�صابة باأمرا�ض القلب التاجية يف الوقاية االأولية والثانوية. هناك حاجة ملحة لتحديد اأي من 
املر�صى ينبغي اأن ُيعالج، واأي منهم الذي يجب اأن ُي�صتهدف للتدخل املبكر.
مفتاح الكلمات: الربوتني الدهني )اأ(؛ ال�صحوم الثالثية؛ االأوعية التاجية؛ موؤ�رص كتلة اجل�صم؛ ت�صلب ال�رصايني.
abstract: Objectives: This cross-sectional study investigated the association of lipoprotein(a) [Lp(a)] levels  as 
an atherosclerosis predictor and their relationship to the severity of coronary artery disease (CAD). Methods: 
360 consecutive patients at Sanjay Gandhi Postgraduate Institute of Medical Sciences and King George’s Medical 
University hospitals, Lucknow, North India, with chest pains, CAD symptoms and on lipid-lowering therapy were 
enrolled between June 2009 and October 2011. Before coronary artery angiography (CAG), a fasting blood sample was 
assessed for lipid and Lp(a) levels. The synergy between percutaneous coronary intervention with taxus and cardiac 
surgery (SYNTAX) score was calculated according to the CAG results. Patients were divided into 3 groups based on 
CAD severity and SYNTAX scores. Results: Angiography revealed CAD in 270 patients. Lp(a) levels were higher in 
CAD compared to non-CAD patients (48.7 ± 23.8 mg/dl versus 18.9 ± 11.1 mg/dl [P <0.0001]). The levels of Lp(a)
were lower in single than in double and triple vessels (39.3 ± 18.4 mg/dl versus 58.0 ± 23.0 mg/dl, and 69.2 ± 
24.1 mg/dl, [P <0.05]). Lp(a) levels were significantly higher in severe CAD with SYNTAX score >30 (88.0±24.0 
mg/dl). Lp(a) levels correlated significantly with SYNTAX scores (r = 0.70, P <0.0001). Conclusion: In this study, 
Lp(a) levels were positively associated with a patient’s SYNTAX score in diseased vessels. Furthermore, an elevated 
Lp(a) level was a causal, independent risk factor of CAD. Lowering Lp(a) levels would reduce CAD in primary and 
secondary prevention settings. There is an urgent need to define more precisely which patients to treat and which 
to target for earlier interventions. 
Keywords: Lipoprotein (a); Triglycerides; Coronary vessels; Body mass index; Atherosclerosis.
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Advances in Knowledge
- This study establishes the level of lipoprotein (a) [Lp(a)] which could be a predictive factor for angiographic-proven coronary artery 
disease (CAD) in northern Indians.
- High levels of triglycerides (TG) are a contributing factor in atherosclerosis. An increase in atherogenic particles, especially small dense 
low-density lipoprotein (LDL) cholesterol, may be a causative factor for the initiation and precipitation of coronary atherosclerosis.
- Every region and race must have standardised cut-off levels for the early detection and prevention of CAD. 
Application to Patient Care 
- The study indicates that the presence of Lp(a) is strongly associated with the level of severity of coronary atherosclerosis even in the case 
of normal total cholesterol, moderately increased TG, and low high-density lipoprotein (HDL) cholesterol levels in patients.
- Intervention with Lp(a)-lowering agents are required to prevent progressive coronary disease.
- It may be helpful to estimate serum TG levels to identify the presence of CAD even in patients who are receiving treatments such as 
hypolipidemic drugs like statins.
Atherosclerosis is a disease of large and medium-
sized arteries such as the carotid and coronary 
arteries, and arteries of the lower extremities. 
It is characterised by focal lesions of one of the 
following types: fatty streak, fibrous plaque, or 
complicated lesions. A great number of hypotheses 
have been published about the pathogenesis of 
atherosclerosis, such as the lipid hypothesis, 
thrombogenic hypothesis, and the endothelial cell 
injury hypothesis. Many epidemiological studies 
have revealed that chronically elevated lipid and 
cholesterol levels are associated with an increased 
incidence of atherosclerosis.1 Approximately 20% 
of the general population has high circulating levels 
of lipoprotein(a) [Lp(a)].2 
The presence of Lp(a) has emerged as a powerful 
genetic risk factor for coronary artery disease 
(CAD).3–5 It is a complex molecule of low-density 
lipoprotein (LDL) to which a large, hydrophilic 
glycoprotein, apolipoprotein (a) [Apo(a)], is 
covalently linked via disulfide bonds. Based on 
its structure, Lp(a) has both atherogenic and 
prothrombotic properties.6
In advanced atherosclerosis, Lp(a) is an 
independent risk factor not dependent on LDL. 
Lp(a) represents a coagulant risk of plaque 
thrombosis.7 Apo(a) contains domains that are very 
similar to plasminogen, whose main function is to 
dissolve fibrin blood clots. Lp(a) accumulates in the 
vessel wall and inhibits the binding of plasminogen 
to the cell surface. This inhibition of Lp(a) also 
promotes the proliferation of smooth muscle cells. 
This unique feature suggests it causes the generation 
of clots and atherosclerosis. 
Triglyceride-(TG) rich lipoproteins, which 
originate both in the intestines and liver, are 
considered an atherogenic factor.8,9 The aim of this 
study was to evaluate, in judging the severity of 
CAD, the association between the level of Lp(a) as a 
biomarker, and lipid status.
Methods
A cross-sectional study was conducted on 360 
consecutive patients (300 male and 60 female) 
who underwent coronary angiography between 
June 2009 and October 2011 at the Sanjay Gandhi 
Postgraduate Institute of Medical Sciences and 
the King George’s Medical University (KGMU) 
tertiary care hospitals in Lucknow, Uttar Pradesh, 
North India. The study was approved by KMGU's 
ethics committee. Subjects were informed of the 
objectives and procedure of the study and informed 
consent was taken with the consent form in both 
English and Hindi. The patients’ demographic 
profiles, socioeconomic status, personal habits, and 
disease risk factor histories were recorded. Blood 
pressure (BP) was measured before the patients 
were sent to the catheterisation laboratory.
Patients with a history of chest pain, angina, 
acute myocardial infarction (AMI), non ST-segment 
elevation myocardial infarction (NSTEMI), 
unstable angina, and stable angina were included. 
All patients received long-term treatment with 
angiotensin-converting-enzyme (ACE) inhibitors, 
calcium (Ca) antagonists, or α- and β-adrenergic 
blocking agents. Almost all cases received statin 
treatment—most frequently atorvastatin. Patients 
with nephrotic syndrome, acute or chronic 
renal failure, thyroid disorders, acute infections, 
stroke, or diabetic ketoacidosis were excluded. 
Coronary angiography was performed using 
the Judkins technique, or a radial approach.10 
Coronary angiography results were evaluated by 
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interventional cardiologists, who were blinded to 
the serum Lp(a) analysis. In coronary angiography, 
the complexity of CAD was determined by an 
angiographic grading tool—the synergy between 
percutaneous coronary intervention with taxus and 
cardiac surgery (SYNTAX) score.11-12 In principle, 
the SYNTAX score is the sum of the points assigned 
to each individual lesion identified in the coronary 
tree with >50% narrowing in the diameter of the 
vessels that measure greater than 1.5 mm. The 
percentage of stenosis was not a consideration. Only 
the presence of a stenosis from 50–99% in diameter, 
a narrowing of less than 50% in diameter, or a total 
occlusion were considered. The entire patient group 
was divided into two subgroups: subjects with CAD 
who had a SYNTAX score >0 and subjects without 
significant coronary artery stenosis with a SYNTAX 
score of 0.
Fasting blood samples were collected after a 10 
to 12 hour fast and before cardiac catheterisation. 
Samples were taken in sterile tubes, centrifuged at 
3000 rpm for 10 minutes at 4°C, and then stored 
at -80°C until assayed. Fasting blood glucose 
(FBG), serum total cholesterol, high-density 
lipoprotein cholesterol (HDL-C), serum TG, and 
LDL-cholesterol (LDL-C) levels were estimated 
by standard methods. Lp(a) was measured by 
agglutination due to an antigen-antibody reaction 
between Lp(a) in a sample and anti-Lp(a) antibodies 
absorbed to latex particles. The assay range is 
approximately 3–90 mg/dl. Higher values of Lp(a) 
were rechecked by diluting the sample with normal 
saline. Results were then standardised.
The results are presented in mean ± standard 
deviation (SD) and percentage. The unpaired t-test 
was used to compare the two continous variables 
and one way analysis of variance (ANOVA) was 
used to compare more than two continous variables. 
The 95% confidence interval (CI) of means was 
also calculated. The Pearson correlation coefficient 
was calculated to find out the correlation between 
two variables. The P value <0.05 was considered 
significant. All the analysis was carried out by 
using the Statistical Package for the Social Sciences 
(SPSS), Version 15.0 (IBM, Chicago, IL, USA). 
Results
The mean age of the patients was 54.0 ± 8.0 years, 
ranging from 30–65 years. A total of 270 patients 
(75%) of the 360 patients had angiographically-
Table 1: Comparison of clinical and biochemical 
parameters between coronary artery disease (CAD) and 
non-CAD patients as defined by angiography
Parameters CAD 
(SYNTAX 




score = 0) 
(n = 90)
P value
SBP (mmHg) 142 ± 18 138 ± 16 <0.001
DBP (mmHg) 86 ± 10 82 ± 11 <0.001
BMI (kg/m2) 26 ± 2.1 24.9 ± 2.7 <0.001
TC (mmol/l) 3.9 ± 0.8 
(150.8 ± 30.2)




TG (mmol/l) 2.1 ± 0.5 
(182.8 ± 43.9)





0.8 ± 0.2 (30.9 
± 7.5)





2.2 ± 0.7 
(83 ± 28.9)





0.9 ± 0.2 
(36 ± 9.2)











All results expressed in mean and standard deviation (SD). All values 
are reported in mmol/l and mg/dl, respectively.
CAD = coronary artery disease; SYNTAX = synergy between 
percutaneous coronary intervention with taxus; SBP= systolic blood 
pressure; DBP = diastolic blood pressure; BMI = body mass index; TC = 
total cholesterol; TG = triglycerides; HDL-C = high density lipoproteins 
cholesterol; LDL-C = low density lipoproteins cholesterol; VLDL-C = 
very low density lipoproteins cholesterol; Lp(a) = Lipoprotein(a).
Table 2: Lipoprotein(a) levels in normal coronary and 
diseased vessels


























49 69 ± 24 
(22.8–110)
62.29–76.76
F and P values 95.72; <0.001
Lp(a) = Lipoprotein(a); SD = standard deviation; CI = confidence 
interval; *Significantly different from single, double and triple vessel 
disease (P <0.0001); †Significantly different from double and triple 
vessel disease (P <0.0001); ‡Significantly different from triple vessel 
disease (P = 0.01) (Holm-Bonferroni multiple comparison test.).
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proven CAD and 90 (25%) had normal coronary 
arteries (non-CAD group). The systolic and 
diastolic blood pressure was significantly higher in 
CAD patients (P <0.001) as compared to the non-
CAD patients. The body mass index (BMI) was 
significantly higher in CAD patients (P <0.0001) as 
compared to non-CAD patients. There was a highly 
significant difference (P <0.0001) in the level of TG 
between CAD (2.0 ± 0.5 mmol/l) and non-CAD 
(1.4 ± 0.5 mmol/l) patients. A highly significant 
difference was observed in the level of very low 
density lipoproteins (VLDL) between CAD (0.9 
± 0.2 mmol/l) and non-CAD (0.6 ± 0.2 mmol/l) 
patients. However, the HDL was significantly lower 
(P <0.0001) in CAD patients (0.8 ± 0.2 mmol/l) as 
compared to non-CAD (1.0 ± 0.2 mmol/l) patients. 
Lp(a) levels were significantly higher in CAD (49 ± 
24 mg/dl) than non-CAD patients (19 ± 11 mg/dl) 
[Table 1].
Parameters were compared by vessel grades-
Lp(a) levels were significantly different among 
normal and different grades (P <0.0001). The Holm-
Bonferroni pairwise comparison test showed that 
lipoprotein levels were significantly higher in all 
diseased vessels than those categorised as normal 
(P <0.0001) [Table 2]. CAD subjects with diseased 
vessels had higher TG and VLDL levels, and lower 
HDL cholesterol concentrations in diseased vessels 
as compared to people with normal coronary status 
[Table 3].
A subgroup analysis indicated that Lp(a) levels 
were significantly  higher (P <0.0001) in patients 
with TG levels ≥150 mg/dl (47.6 ± 25.1 mg/dl) as 
compared to those with TG levels of <150 mg/
dl (25.2 ± 15.6 mg/dl). However, Lp(a) was higher 
(P <0.0001) in those with HDL-C levels of ≤40 mg/
dl (43.6 ± 24.9 mg/dl) than those with levels >40 
(26.7 ± 20.0 mg/dl). Furthermore, Lp(a) levels were 
significantly lower (P <0.0001) among those whose 
TG levels were <150 mg/dl and HDL was >40 mg/
dl (15.6 ± 8.9 mg/dl) as compared to others (43.3 ± 
24.6 mg/dl) [Table 4].
CAD patients were classified according to 
their SYNTAX scores: <20, 20–30, and >30; Lp(a) 
levels in these subgroups were analysed and 
found significantly different [Table 5]. According 
to the correlation coefficient, there was a positive 
association between Lp(a) levels and SYNTAX 
scores for the diseased vessel patient group (r = 
0.70, P <0.0001) [Figure 1].
Discussion
In this study, Lp(a) level >20 mg/dl was not only 
associated with the presence of coronary disease but 
also with the severity of the coronary atherosclerosis. 
This finding is consistent with previous reports.13 
A study carried out in southern India reported 
the cut-off level of Lp(a) as being 25 mg/dl for 
determination of a patient’s risk of coronary heart 
disease (CHD).14 Higher mean levels of Lp(a) were 
observed in our cases as compared to the control 
group in studies reported in other parts of India, 
where levels ranged from 12 to 41 mg/dl in CAD 
patients, and 8 to 24 mg/dl in healthy controls.15–18 
Mean Lp(a) levels in patients in our study were 
also within the range of values reported in earlier 
Indian studies.19 Upper limits of normal Lp(a) have 
not been defined in the Indian population.15 In 
Caucasians, an Lp(a) of 30 mg/dl is considered the 
upper limit of normal. Erbagci et al. showed that 
the optimal cut-off values for Lp(a) levels were 22.6 
and 9.8 mg/dl for men and women, respectively, 
in cases of CHD, with or without angiographically 





NC SVD DVD TVD P value
TC 3.6 ± 0.8 (140 ± 30) 3.0 ± 0.7 (151 ± 28) 3.9 ± 0.9 (152 ± 35) 3.8 ± 0.8 (148 ± 31) 0.78
TG 1.4 ± 0.5 (124 ± 44) 1.9 ± 0.4 (177 ± 39) 2.1 ± 0.5 (187 ± 42) 2.2 ± 0.6 (197 ± 57) <0.001 
HDL-C 1.0 ± 0.2 (40 ± 9) 0.8 ± 0.2 (31 ± 7) 0.8 ± 0.2 (31 ± 8) 0.8 ± 0.2 (30 ± 6) <0.001
LDL-C 1.4 ± 0.7 (75 ± 27) 2.2 ± 0.7 (84 ± 27) 2.2 ± 0.8 (83 ± 32) 2.0 ± 0.7 (79 ± 29) 0.08
VLDL-C 0.6 ± 0.2 (25 ± 9) 0.9 ± 0.2 (35 ± 8) 0.9 ± 0.2 (37 ± 8) 1.0 ± 0.3 (39 ± 12) <0.001
NC = normal coronary; SVD = single vessel disease; DVD = double vessel disease; TVD = triple vessel disease; TC = total cholesterol; TG = 
triglycerides; HDL-C = high density lipoproteins cholesterol; LDL-C = low density lipoproteins cholesterol; VLDL-C = very low density lipoproteins 
cholesterol.
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coronary status. High TG levels in our patients 
appeared to contribute to CAD risk. TG levels >130 
mg/dl are strongly associated with the extent of a 
patient’s coronary atherosclerosis; therefore, the 
present coronary angiography proven study is in 
agreement with the documented epidemiologic 
observations reported by Austin, which was that 
hypertriglyceridemia commonly occurrs in CAD 
patients [Table 3].21-23
A delayed clearance of VLDL and chylomicron, 
and/or increased hepatic production of large VLDL 
results in the increased production of precursors of 
small dense LDL particles, a phenotype of which was 
reported to be associated with increased production 
of potentially atherogenic remnant-like particles.24 
Enrichment of the TG of this product through the 
action of cholesteryl ester transfer protein, together 
with hydrolysis of TG by hepatic lipase leads to an 
increased production of small dense LDL. Increased 
demonstrable lesions.20 Our results showed Lp(a) 
as 21.4 mg/dl in minimal angiographically-proven 
single vessel disease even when cardiovascular 
risk factors and specific treatments (statins and/or 
aspirin) were taken into account; therefore, a level 
>20 mg/dl should be considered the cut-off value in 
the northern Indian population [Table 2].
Contrary to the notion that these risk factors 
are highly prevalent in northern Indians, we found 
increased TG and very low HDL levels in diseased 
vessel patients as compared to those with normal 
Table 4: Lipoprotein(a) levels as a subgroup of 
triglycerides and high-density lipoprotein cholesterol 
(HDL-C) parameters
Parameters No. Lp(a) mg/dl P value
TG
                <150 mg/dl 102 25.2 ± 15.6  
<0.001
                >150 mg/dl 258 47.6 ± 25.1
HDL-C
                    <40 mg/dl 311 43.6 ± 24.9  
<0.001
                    >40 mg/dl 49 26.7 ± 20.0
TG <150 and HDL-C




<0.001TG >150 and HDL-C
                   <40 mg/dl 334 43.3 ± 24.6
TG = Triglycerides; HDL-C = high density lipoprotein cholesterol; 
Lp(a) = Lipoprotein (a).
Table 5: Lipoprotein(a) level by synergy between 
percutaneous coronary intervention with taxus and 
cardiac surgery (SYNTAX) score
SYNTAX Score No. of Patients Lipoprotein(a) 
mg/dl
<20 226 42 ± 18
20–30 21 75 ± 16
>30 23 88 ± 24
 
Figure 1: Scatter diagram showing the correlation between lipoprotein (a) [Lp(a)] levels and synergy between 
percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) scores.
Pearson correlation  coefficient (r = 0.70, P <0.0001) 
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levels of small dense LDL have been identified as 
a risk factor for an increased incidence of CAD in 
several epidemiological studies.25
Furthermore, a subgroup analysis of TG and 
HDL-C cut-offs showed significant Lp(a) variation 
in our study. Significantly higher Lp(a) levels 
increased TG >150 mg/dl and it was also observed 
that Lp(a) levels markedly increased in subjects with 
low levels of HDL-C (P <.0001). Lp(a) levels depend 
on lipid profiles and suggest that treatment of 
dyslipidemia may also affect Lp(a) concentrations. 
Future studies are needed to clarify common 
mechanisms, enzymes, and receptors involved in 
Lp(a) and HDL/TG metabolism with a focus on 
how these mechanisms are modified in the setting 
of hypertriglyceridemia.
A marked raise in Lp(a) levels was found in 
patients with a SYNTAX score >30 (88 ± 24mg/
dl). Subjects with an intermediate to high SYNTAX 
score (20–30) observed higher Lp(a) levels (75 
± 16 mg/dl, P = 0.0001] as compared to subjects 
with low SYNTAX scores <20 (42 ± 18 mg/dl). 
These values shows that Lp(a) is directly related to 
SYNTAX score grading of atherosclerotic lesions. 
Our findings show that Lp(a) levels correlate with 
CAD severity [Table 5] and with SYNTAX scores. 
Assuming that the SYNTAX score has the ability 
to describe anatomical and functional features of 
CAD, we suggest that Lp(a) levels can predict the 
extent of coronary artery impairment. The SYNTAX 
score predicts mortality and morbidity in patients 
irrespective of disease severity, at both short- and 
long-term follow-ups. The relationship between 
Lp(a) and the extent of CAD assessed by SYNTAX 
score had not been investigated in previous studies.
The mechanism implicated in the atherogenicity 
of Lp(a) includes proatherogenic Lp(a), via its apo(a) 
moiety, which is a proinflammatory molecule that 
directly interacts with the leukocyte β2-integrin 
Mac-1, thereby facilitating the  recruitment of 
inflammatory cells. TGF-β1 activation is another 
mechanism via which Lp(a) contributes to the 
development of atherosclerotic vasculopathies. 
TGF-β1 is subject to proteolytic activation by 
plasmin and its active form leads to an inhibition of 
the proliferation and migration of smooth muscle 
cells, which play a central role in the formation and 
progression of atherosclerotic vascular diseases. 
If TGF-β1 fails to be activated, for example due 
to Lp(a) accumulation in the vascular wall, it is 
associated with an increased proliferation and 
migration of the smooth vascular muscle cells and 
the formation of atherosclerotic lesions.26
In assessing appropriate cardiovascular 
preventive measures, clinical investigations using 
niacin alone or in combination with other lipid-
lowering agents such as statins have provided 
evidence for its dose-dependent cardiovascular 
benefit of up to 40%, and its amelioration of the 
global cardiovascular risk profile of patients.27,28 
Bruckert et al. published a meta-analysis of 11 
randomised controlled trials, involving 2,682 
patients in the active group and 3,934 in the 
control group, which examined the effects of 
niacin alone or in combination with other lipid-
lowering drugs on cardiovascular events and 
atherosclerosis.29 Recently, a report suggested that 
a 2-month treatment with a ginkgo biloba extract 
reduced Lp(a), with results attributed due to the 
anti-inflammatory effect of this natural extract.30 
Finally, there is reliable evidence to show that 
antiplatelet therapy with aspirin decreases platelet 
function, and may decrease plasma Lp(a) as well. 
The physiological basis of this pleiotropic effect of 
aspirin is still uncertain, although it may decrease 
the hepatic synthesis of apo(a) by inhibiting the 
transcriptional activity of the gene and suppressing 
messenger ribonucleic acid (RNA) expression.31 
Other studies investigated the effect of other 
compounds like carnitine and coenzyme Q10.32–37
A large number of apheresis techniques have 
been described based on plasma separation (lipid 
filtration, LDL-precipitation, and direct adsorption 
of lipoproteins). All methods have been primarily 
developed for treatment of high plasma LDL 
concentrations. However, because of the numerous 
structural similarities between LDL and Lp(a), the 
effect of these methods on both lipoproteins is 
very similar. Essentially, depending on the treated 
plasma or blood volume concentrations of Lp(a) 
and LDL, levels are lowered by 50–74 %, and 
>60 % at each therapy. Even other haemorheological 
parameters such as fibrinogen and viscosity are 
positively influenced.38 
This study confirms Lp(a) levels >20 mg/dl as 
a cut-off value to predict the severity of coronary 
atherosclerosis, suggesting that Lp(a) levels should 
be determined in patients with CAD, especially in 
normolipidemic individuals. Lp(a), considered an 
emerging risk factor by the National Cholesterol 
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Amouyel P, et al. Lipoprotein(a) as a predictor 
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7. Caplice NM, Panetta C, Peterson TE, Kleppe LS, 
Mueske CS, Kostner GM, et al. Lipoprotein(a) binds 
and inactivates tissue factor pathway inhibitor; a 
novel link between lipoproteins and thrombosis. 
Blood 2001; 98:2980–7.
8. Philips NR, Waters D, Havel RJ. Plasma lipoproteins 
and progression of coronary artery disease evaluated 
by angiography and clinical events. Circulation 1993; 
88:2762–70.
9. Zilversmit DB. Atherogenic nature of triglycerides, 
postprandial lipemia, and triglyceride-rich remnant 
lipoproteins. Clin Chem 1995; 41:153–8.
10. Judkins MP. A Percutaneous transfemoral technique. 
Radiology 1967; 89:815–21.
11. Serruys PW, Morice MC, Kappetein AP, Colombo 
A, Holmes DR, Mack MJ, et al. For the SYNTAX 
investigators. Percutaneous coronary intervention 
versus coronary artery bypass grafting for severe 
coronary artery disease. N Engl J Med 2009; 
360:961–72.
12. Sianos G, Morel MA, Kappetein AP, Morice M-C, 
Colombo A, Dawkins K, et al. The SYNTAX score: 
An angiographic tool grading the complexity of 
CAD. EuroIntervention 2005; 1:219–27.
13. Velmurugan K, Deepa R, Ravikumar R, Enas EA, 
Lawrence JB, Anshoo H, et al. Relationship of 
lipoprotein(a) with initmal medial thickness of the 
carotid artery in type 2 diabetic patients in south 
India. Diabet Med 2003; 20:455–61.
14. Rajasekhar D, Saibaba KSS, Srinivasa Rao PVLN, 
Latheef SAA, Subramanyam G. Lipoprotein(a): 
Better assessor of coronary heart disease risk in 
south Indian population. Indian J Clin Biochem 
2004; 19:53–9.
15. Gambhir JK, Harsimrut K, Gambhir DS, Prabhu 
KM. Lipoprotein(a) as an independent risk factor for 
coronary artery disease in patients below 40 years of 
age. Indian Heart J 2000; 52:411–5.
16. Muthuswamy V, Amuthan V, Kumaravel V. 
Lipoprotein(a) and premature coronary artery 
disease. Indian Heart J 2000; 52:765.
Education Program’s (NCEP) Adult Treatment 
Panel (ATP) III, has been implicated in the 
development of the premature atherosclerotic 
disease seen in South Asians.39 Among patients 
with excessive Lp(a), CAD risk increases 3-fold in 
the absence of other risk factors. The risk increases 
8-fold with low HDL-C, 12-fold with high LDL-C, 
16-fold with diabetes, and 25-fold with a TC/
HDL-C ratio. The higher the Lp(a) level the lower 
the age of first heart attack, and the most affected 
individuals develop myocardial infarction (MI) by 
the third to fifth decade of life. High levels of Lp(a) 
correlate with the prematurity, severity, extent, and 
progression of coronary atherosclerosis as well as 
the occurrence and recurrence of MI among Asian 
Indians.40 Although all patients with hypertension 
and CAD require aggressive risk modification, the 
subgroup with high Lp(a) and TG levels may have 
multiple-vessel involvement and probably will need 
close clinical surveillance.  
There are limitations to our study. The enrolled 
subjects might not be representative of the entire 
CAD population, as subjects recruited were referred 
to tertiary care for a coronary angioplasty restenosis 
trial (CART) and percutaneous transluminal 
coronary angioplasty (PTCA) and SYNTAX score 
grading considers over 50% coronary artery luminal 
reduction. The generally used estimation of luminal 
reduction is not exact and can be incorrect in spite 
of an investigator’s experience.
Conclusion
In conclusion, this cross-sectional analysis suggests 
that Lp(a) levels differ significantly among Indians. 
The association between Lp(a) and cardiovascular 
outcomes may differ by race/ethnicity as well. 
Further studies should strive to disaggregate 
racial/ethnic groups and stratify by gender when 
examining Lp(a) among Asians. If replicated, our 
study suggests that the determination of Lp(a) levels 
may be particularly important in Asian Indians for 
the prevention of cardiovascular disease. 
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